Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06413433 · ClinicalTrials.gov registry record · Phase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
A Phase 3 study of Binge-Eating Disorder, sponsored by Axsome Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06413433: Recruiting Phase 3 study of Binge-Eating Disorder, sponsored by Axsome Therapeutics.
NCT06413433 is a Phase 3 study of Binge-Eating Disorder that is actively recruiting participants, run by Axsome Therapeutics. The registered enrollment target is 450 participants, below the 1,131-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06413433, a Phase 3 study of Binge-Eating Disorder, is actively recruiting participants, sponsored by Axsome Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Solriamfetol 150 mg
- DRUG Solriamfetol 300 mg
Study Locations (20)
Florida
- Clinical Research Site - Clermont
- Clinical Research Site - Fort Myers
- Clinical Research Site - Hialeah
- Clinical Research Site - Jacksonville
- Clinical Research Site - Lauderhill
- Clinical Research Site - Miami
- Clinical Research Site - Miami
- Clinical Research Site - Miami Lakes
- Clinical Research Site - Orlando
- Clinical Research Site - Orlando
California
- Clinical Research Site - Encino
- Clinical Research Site - Garden Grove
- Clinical Research Site - Long Beach
- Clinical Research Site - Newport Beach
- Clinical Research Site - San Diego
- Clinical Research Site - Santa Ana
- Clinical Research Site - Walnut Creek
- Clinical Research Site - West Covina
Colorado
- Clinical Research Site - Colorado Springs
Connecticut
- Clinical Research Site - Cromwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-04-26 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
What NCT06413433 shows while recruiting
NCT06413433 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 1,131-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06413433 names 20 study sites across 4 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06413433 about?
NCT06413433 is a clinical study titled "Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol". ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
What is the current status of trial NCT06413433?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-04-26. Estimated completion is 2025-12.
What conditions does trial NCT06413433 study?
This clinical trial studies the following conditions: Binge-Eating Disorder.
What interventions are being tested in trial NCT06413433?
The interventions under investigation include: Placebo (DRUG), Solriamfetol 150 mg (DRUG), Solriamfetol 300 mg (DRUG).
Who is sponsoring clinical trial NCT06413433?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06413433 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Binge-Eating Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06413433's enrollment target sits among peer trials
450 4th of 37 higher than 34 of 37 other Binge-Eating Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Binge-Eating Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
COMPLETED · Phase 3
-
Open Label Extension in Adults With Binge Eating Disorder (BED)
COMPLETED · Phase 3
-
Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder
RECRUITING · NA
-
Eating Disorders Genetics Initiative 2
RECRUITING
-
Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
RECRUITING · NA
-
Project THINK: Trajectories of Health, Ingestive Behaviors, and Neurocognition in Kids
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI